Literature DB >> 7957239

Interleukin-1-induced prostaglandin E2 biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A2 and cyclooxygenase-2.

J Angel1, F Berenbaum, C Le Denmat, T Nevalainen, J Masliah, C Fournier.   

Abstract

Treatment of human synovial cells with interleukin-1 (IL-1) results in a large increase in the production of prostaglandin E2 (PGE2), a function in which the activation of phospholipase A2 (PLA2) is a key step. In order to identify the enzymes that are linked to IL-1-mediated arachidonate availability and subsequent PGE2 production, we have investigated the changes in gene expression of the 85-kDa cytosolic PLA2 (cPLA2), the 14-kDa secretory PLA2 (sPLA2) and the two forms of cyclooxygenase in human synoviocytes after stimulation with recombinant IL-1 beta. Northern-blot analysis revealed that both cPLA2 and cyclooxygenase-2 mRNA were progressively upregulated upon exposure to IL-1 for 5 hours and the glucocorticoid, dexamethasone, blocked the increased expression of these two genes. In contrast, IL-1-induced sPLA2 gene expression determined in the same cell samples was weak and most often rapid, and dexamethasone further stimulated it. In addition, IL-1 did not modify the levels of the constitutive cyclooxygenase-1. The cPLA2 and cyclooxygenase-2 enzymic activities are dependent upon de novo synthesis of mRNA and protein, since they were inhibited by actinomycin D and cycloheximide. Our data suggest that the IL-1-induced production of PGE2 in human synoviocytes can be attributed to the stimulation of both cPLA2 and cyclooxygenase-2. These enzymes may represent appropriate targets for selective blockade of prostanoid production in the inflammed joints.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957239     DOI: 10.1111/j.1432-1033.1994.tb20033.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  20 in total

1.  The regulation of prostaglandin output from term intact fetal membranes by anti-inflammatory cytokines.

Authors:  N L Brown; S A Alvi; M G Elder; P R Bennett; M H Sullivan
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Interleukin-4 inhibits prostaglandin E2 production by freshly prepared adherent rheumatoid synovial cells via inhibition of biosynthesis and gene expression of cyclo-oxygenase II but not of cyclo-oxygenase I.

Authors:  E Sugiyama; H Taki; A Kuroda; T Mino; N Yamashita; M Kobayashi
Journal:  Ann Rheum Dis       Date:  1996-06       Impact factor: 19.103

3.  Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells.

Authors:  F Lapicque; P Vergne; J Y Jouzeau; D Loeuille; P Gillet; E Vignon; P Thomas; P Velicitat; D Türck; C Guillaume; A Gaucher; P Bertin; P Netter
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

4.  EP4 receptor regulates collagen type-I, MMP-1, and MMP-3 gene expression in human tendon fibroblasts in response to IL-1 beta treatment.

Authors:  Bhavani P Thampatty; Hongxia Li; Hee-Jeong Im; James H-C Wang
Journal:  Gene       Date:  2006-09-15       Impact factor: 3.688

5.  Posttranscriptional effect of insulin-like growth factor-I on interleukin-1beta-induced type II-secreted phospholipase A2 gene expression in rabbit articular chondrocytes.

Authors:  C Jacques; G Béréziat; L Humbert; J L Olivier; M T Corvol; J Masliah; F Berenbaum
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

6.  PLIP, a novel splice variant of Tip60, interacts with group IV cytosolic phospholipase A(2), induces apoptosis, and potentiates prostaglandin production.

Authors:  A M Sheridan; T Force; H J Yoon; E O'Leary; G Choukroun; M R Taheri; J V Bonventre
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

7.  Fasitibant prevents the bradykinin and interleukin 1β synergism on prostaglandin E₂ release and cyclooxygenase 2 expression in human fibroblast-like synoviocytes.

Authors:  S Meini; P Cucchi; L Tinti; S Niccolini; F Bellucci; C Catalani; C Valenti; M Galeazzi; A Fioravanti; C A Maggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-26       Impact factor: 3.000

8.  Prevention of lipopolysaccharide-induced intussusception in mice by the COX2 inhibitor rofecoxib.

Authors:  Mahmoud Badriyyah; Haggi Mazeh; Stefan Brocke; Venera Osmanova; Herbert R Freund; Menachem Hanani
Journal:  Pediatr Surg Int       Date:  2007-11-06       Impact factor: 1.827

9.  Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis.

Authors:  G D Anderson; S D Hauser; K L McGarity; M E Bremer; P C Isakson; S A Gregory
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

10.  Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10.

Authors:  S Poole; F Q Cunha; S Selkirk; B B Lorenzetti; S H Ferreira
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.